So far this has been a great year for biotech, as investors have been more than happy to look past the risks and embrace the opportunities in the pipeline. While Rigel Pharmaceuticals (RIGL) has certainly gone along for the ride, investors may yet have reason to think about adding shares of this potential star to their portfolio.
A One-Drug Story Today, But What A Drug
Teasing out biotech valuation is always a subjective exercise, but I don't think too many Rigel longs are going to quibble with the statement that R788 (fostamatinib disodium), also known as FosD, is a huge part of the company's current value.
FosD is an oral syk inhibitor that has shown very encouraging efficacy in rheumatoid arthritis. The potential of this drug early on was such that the company was able to sign a lucrative partnership with AstraZeneca (AZN) and the end of the pivotal development process is in sight.
Read more here:
Rigel Pharma Has More Room To Run
No comments:
Post a Comment